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ABSTRACT 
Ubiquitin-tagged substrates are degraded by the 26S proteasome; a multi-subunit 
complex comprising a proteolytic 20S core particle (20S CP) capped by 19S 
regulatory particles (19S RP) 1,2. The approval of bortezomib for the treatment of 
multiple myeloma has validated the 20S CP as an anti-cancer drug target 3. Here, we 
describe the small molecule b-AP15 as a novel class of proteasome inhibitor that 
abrogates the deubiquitinating (DUB) activity of the 19S RP. b-AP15 inhibited the 
activity of two 19S RP-associated DUBs, ubiquitin carboxyl-terminal hydrolase 5 
(UCHL5) and ubiquitin specific peptidase 14 (USP14), resulting in accumulation of 
polyubiquitin. b-AP15 induced tumor cell apoptosis insensitive to TP53 status and 
over-expression of the apoptotic inhibitor Bcl-2. We show that treatment with b-AP15 
inhibited tumor progression in four different in vivo solid tumor models and inhibited 
organ infiltration in an acute myeloid leukemia (AML) model. Our results show that 
the DUB activity of the 19S RP is a novel anti-cancer drug target. 
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We identified b-AP15 (Fig. 1a) in a screen for compounds that induce the lysosomal 
apoptosis pathway 4,5. To characterize the connection between b-AP15 and other anti-
cancer drugs we compared the gene expression signature of b-AP15- treated cells to a 
collection of expression signatures for >1300 bioactive compounds in the CMAP 
database (www.broad.mit.edu/cmap) 6. b-AP15 induced a gene expression profile 
similar to that of several well characterized proteasome inhibitors 7-10 (Fig. 1b, 
Supplementary Spreadsheet). To test whether b-AP15 blocked cellular proteasome 
function we utilized a reporter cell line expressing ubiquitin tagged to yellow 
fluorescent protein (UbG76V-YFP) that is constitutively targeted for proteasomal 
degradation 11. We observed a dose-dependent accumulation of the UbG76V-YFP 
reporter (IC50=0.8 µM), indicating impaired proteasome degradation (Fig. 1c). 
Defects in ubiquitin turnover are a characteristic of proteasome inhibition 12. We 
indeed observed rapid accumulation of polyubiquitin in b-AP15-treated colon 
carcinoma HCT-116 cells, with a similar kinetic but higher molecular weight than that 
of the 20S CP inhibitor bortezomib, suggesting inhibition of the ubiquitin-proteasome 
system (UPS) (Fig. 1d). The UPS controls the turnover of many cell cycle regulatory 
proteins including inhibitors of the cyclin-dependent kinases, CDKN1A, CDKNIB 
and the tumor suppressor TP53 13-15. Treatment with b-AP15 increased the levels of 
all three in a dose-dependent manner (Fig. 1e), without altering the levels of ornithine 
decarboxylase 1 (ODC1), an ubiquitin-independent proteasome substrate 16 (Fig. 1f). 
Consistent with the accumulation of cell cycle inhibitors, we observed G2/M phase 
cell cycle arrest (Fig. 1g). Cell cycle arrest was not associated with increased levels of 
DNA damage markers such as p-p53 17 or p-H2AX 18 suggesting that b-AP15 is non-
genotoxic (Supplementary Fig. 1).  
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b-AP15 treatment increased the number of hypodiploid cells (Fig. 1g) and was 
associated with increased levels of apoptotic markers, including activated caspase-3, 
caspase-cleaved poly-ADP ribose polymerase (PARP) (Fig. 1e) and cytokeratin-18 
(CK18) (Supplementary Fig. 2a). Apoptosis and decreased cell viability 
(Supplementary Fig. 2b) was observed at drug concentrations that induced 
polyubiquitin accumulation; thus providing a link between proteasome inhibition and 
cytotoxicity. Notably we found that b-AP15 was more toxic to HCT-116 cells 
compared to immortalized epithelial cells (hTERT-RPE1) or peripheral blood 
mononuclear cells (PBMC) (Supplementary Fig. 2c,d). These differences were 
larger than those observed for bortezomib (Supplementary Fig. 2e,f). Bortezomib-
induced apoptosis is sensitive to TP53 status and the expression levels of the anti-
apoptotic Bcl-2 oncogene 19,20. Using isogenic clones of HCT-116, we found that b-
AP15 induced apoptosis which was insensitive to over-expression of Bcl-2 and 
disruption of TP53, as well as BAX and BBC3, mediators of the mitochondrial 
apoptotic pathway (Fig. 1h, Supplementary Fig. 3).  
We next attempted to define how b-AP15 inhibited proteasome activity in vitro. We 
observed no inhibition of any of the proteolytic activities of the proteasome 
(Supplementary Fig. 4), no disassociation of the proteasome or inhibition of 
ubiquitin binding (Supplementary Fig. 5). The chemical structure of b-AP15 
contains a α-ß dienone with two sterically accessible ß-carbons (Fig. 1a). A similar 
pharmacophore was previously described in DUB inhibitors 21. However, when we 
tested cellular DUB activity using ubiquitin 7-amido-4-methylcoumarin (Ub-AMC) 
on b-AP15-treated cells we observed no reduction in total DUB activity 
(Supplementary Fig. 6). Given the similarities in pharmacophore structure and our 
previous data showing that b-AP15 inhibits proteasome activity independently of the 
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20S CP, we hypothesized that b-AP15 may inhibit the proteasome indirectly, by 
blocking the de-ubiquitinating activity of the 19S RP necessary for efficient 
proteasome degradation.  In vitro assays using purified 19S RP or 26S proteasomes 
confirmed that b-AP15 inhibited deubiquitinating activity using a variety of substrates 
including Ub-AMC (Fig. 2a), Ub-GFP 22 (Fig. 2b,c) ubiquitinated HDM2 (Fig. 2d) 
and K48- and K63-linked ubiquitin tetramer chains  (Fig. 2e). This inhibition of chain 
disassembly may account for the accumulation of high molecular weight ubiquitin 
conjugates observed in b-AP15 treated cells (Fig. 1d,e). 
The deubiquitinating activity of the proteasome is attributed to the action of three 
DUBs, UCHL5, USP14 and POH1 all localized within the 19S RP 23-25. UCHL5 and 
USP14 are sensitive to N-ethylmaleimide (NEM), a general inhibitor of cysteine 
proteases, whereas POH1 in contrast is sensitive to the metal chelator N,N,N,N-
Tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN) 26. Residual DUB activity was 
still present after co-treatment of 19S RP with NEM and b-AP15 (Fig. 3a), but 
abolished upon co-treatment of 19S RP with b-AP15 and TPEN (Fig. 3b), suggesting 
that b-AP15 primarily inhibits one or both of the NEM-sensitive cysteine DUBs. The 
β-carbons in b-AP15 may serve as Michael acceptor moieties conferring covalent 
binding to cysteine residues in target proteins. However our in vitro assays showed 
that b-AP15 is a reversible inhibitor (Supplementary Fig. 7a–c) and that glutathione 
does preclude its inhibitory activity (Supplementary Fig. 7d). 
 
To identify which DUBs were inhibited by b-AP15, we performed competitive 
labeling experiments using hemagglutinin tagged ubiquitin vinylsulphonone (HA-
UbVS), an active site directed probe that irreversibly reacts with cysteine DUBs 23. 
Incubation of 19S RP or 26S proteasomes with b-AP15 abolished Ub-VS labeling of 
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two DUBs of molecular weights corresponding to UCHL5 and USP14 (Fig. 3c). We 
observed a similar result using UbVS on lysates derived from drug-treated cells. 
Immunoblot analysis showed a downward shift in the molecular weight of both 
USP14 and UCHL5 due to a loss of activity and decreased UbVS labeling (Fig. 3d). 
We also observed reduced DUB activity in affinity-purified proteasomes, but not in 
cell lysates, from b-AP15-treated cells. (Supplementary Fig. 8a). Consistent with the 
notion that b-AP15 is not a general DUB inhibitor, we observed minimal inhibition on 
recombinant and cytosolic non-proteasomal cysteine DUBs (Supplementary Fig. 
8b,c).  
We next investigated the effect of b-AP15 on tumor growth in vivo. When b-AP15 
was administered daily to SCID mice bearing FaDu squamous carcinoma xenografts, 
we observed significant antitumor activity (treated/control tumor volume, T/C=0.4, 
P=<0.001) (Fig. 4a). When we analyzed tumor death by measuring xenograft-derived 
CK18 in circulation 27,28, we observed a significant increase in the plasma levels of 
total CK18 (P=0.01) along with increased levels of caspase-cleaved CK18 (CK18-
Asp396) (Fig. 4b), showing that b-AP15 has activity against tumor cells in vivo. We 
also examined disease-free survival in Bcl-2 over-expressing HCT-116 colon 
carcinoma xenografts. b-AP15 treatment significantly delayed tumor onset in 
comparison to vehicle-treated control with 2 out of 6 of the treated mice being 
completely disease free at the end of the study (P= 0.0136 by log rank test) (Fig. 4c). 
Similarly, b-AP15 inhibited tumor growth in syngenic mice models using less 
frequent administration schedules. We administered b-AP15 to C57BL/6J mice 
bearing lung carcinomas (LLC) using a 2 day on/2 day off schedule and to BALB/c 
mice bearing orthotopic breast carcinoma (4T1) using a 1 day on/3 day off schedule. 
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b-AP15 significantly inhibited tumor growth in both models with a tumor volume 
response of T/C=0.16, (P=<0.01) and T/C=0.25 (P=<0.001), respectively (Fig. 4d,e). 
We also observed a reduction in the number of pulmonary metastases in the b-AP15- 
treated group of 4T1 breast carcinoma (Fig. 4f). Importantly, we observed no change 
in animal behavior or loss in body weight (Supplementary Fig. 9).  
Since our previous data showed that b-AP15 promoted the accumulation of 
polyubiquitin and inhibited cleavage of K48-linked ubiquitin chains (Fig. 1c,2c), we 
tested the effect of b-AP15 on the UPS activity in vivo by staining tumor sections with 
antibodies to K48-linked polyubiquitin chains. High levels of K48-linked 
polyubiquitin accompanied by caspase-3 activation were observed in the b-AP15- 
treated group, confirming inhibition of DUB activity (Fig. 4g).  
Next, we investigated the effect of b-AP15 on tumor cell invasion in an aggressive 
leukemic model (AML). We administered b-AP15 (daily from d 8 to d 14) to 
C57BL/6J mice bearing C1498 leukemia. Leukemia regression was observed in eight 
out of ten b-AP15-treated mice (P=<0.001) compared to vehicle treated animals 
(n=10). Liver from control animals showed hepatomegaly and massive invasion of 
myeloid leukemic cells into liver tissue (Fig. 4h). In contrast, b-AP15-treated mice 
showed normal structured hepatocytes and lower levels of leukemic blast infiltration. 
Ovary tissue of control mice also showed massive invasion of leukemic blasts and 
interstitial bleeding, not evident in the treated group. Taken together, our results 
demonstrate that b-AP15 inhibits tumor growth in vivo. 
 
Ubiquitin C-terminal hydrolases and ubiquitin specific peptidases are major 
subgroups of the approximately one hundred DUBs encoded by the human genome 29. 
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The reason for specificity of b-AP15 for UCHL5 and USP14 in the 19S RP may be 
related to unique conformations of these enzymes in the 19S RP or due to drug-
induced alterations of the 19S RP structure. Interestingly, a specific inhibitor of 
proteasome bound USP14 was recently described 30. Treatment of cells with this 
inhibitor resulted in enhanced degradation of proteasome substrates. Taken together, 
these different results suggest a degree of redundancy between USP14 and UCHL5 
with regard to ubiquitin disassembly so that cells tolerate the loss of one DUB 
enzyme but not both. Indeed it has been reported that loss of both UCHL5 and USP14 
(but not either alone) leads to the accumulation of polyubiquitinated proteins and 
inhibition of protein degradation without altering the structure or catalytic capabilities 
of the proteasome 31, similar to the phenotype observed following b-AP15- treatment.  
Strong expression of chaperone genes was observed in b-AP15-treated cells 
(Supplementary Table 1,2), showing induction of a proteotoxic response. These 
findings raise the possibility that high molecular weight ubiquitin-substrate complexes 
accumulating as a result of DUB inhibition generate strong cytotoxicity.  
 
We conclude that the DUB activity of the 19S RP is a promising target for cancer 
treatment. The cellular response to b-AP15 is not only distinct to that of bortezomib 
with regard to involvement of apoptosis regulators, but also with regard to the 
sensitivity of tumor cell lines in the NCI-60 cell line panel (http://dtp.nci.nih.gov) 
with colon carcinoma and CNS tumor cell lines being most sensitive (Supplementary 
Fig. 10).  If proven to be effective in the treatment of human malignancies, inhibitors 
of 19S RP DUB activity may display a different therapeutic spectrum than inhibitors 
of 20S enzymatic activity thereby adding to the arsenal of available therapy options.  
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Figure 1: b-AP15 inhibits the ubiquitin-proteasome system. (a) Chemical structure 
of b-AP15 (3,5-bis[(4-nitrophenyl)methylidene]-1-prop-2-enoylpiperidin-4-one). (b) 
Connectivity map of b-AP15 treated MCF7 cells. The top 5 compounds that induce a 
gene expression profile similar to b-AP15 are listed. (c) b-AP15 inhibits degradation 
of ubiquitin-tagged YFP in a proteasome reporter cell line. Levels of UbG76V-YFP 
accumulation was determined by flow cytometry and immunoblotting. (d) 
Immunoblot of ubiquitin conjugation in HCT-116 cells treated with b-AP15 (1 µM) 
or bortezomib (100 nM). (e) Immunoblot of ubiquitin conjugates, caspase 3 activation 
PARP cleavage, TP53, CDKN1A and CDKN1B in HCT-116 cells following 24 h 
treatment with the indicated concentrations of b-AP15. (f) Immunoblot of ODC-1 
levels in HCT-116 cells following treatment with bortezomib (100 nM) or b-AP15 (1 
µM). Values represent quantified optical density units of ODC-1 normalized to ß- 
actin. (g) Cell cycle profiles of b-AP15 treated HCT-116 cells. Cells were analyzed by 
propidium iodide staining and flow cytometry. (h) Levels of caspase activity in 
isogenic HCT-116 cells as determined by ELISA for caspase cleaved cytokeratin-18 
(CK18-Asp396) following treatment with bortezomib (100 nM) or b-AP15 (1 µM) 
(**’P=0.01, ***’P=0.001). 
 
Figure 2: b-AP15 inhibits deubiquitination by the 19S RP. (a) Inhibition of Ub-
AMC cleavage by 19S RP and 26S proteasomes following treatment with b-AP15. 
Ubiquitin aldehyde (Ubal), a general DUB inhibitor is included as a control. (b) 
Immunoblot of 19S RP mediated cleavage of Ub-GFP. 19S RP were pre-treated with 
DMSO or indicated concentrations of b-AP15 followed by addition of recombinant 
Ub-GFP as a DUB substrate. (c) Kinetic of 19S RP Ub-GFP cleavage following b-
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AP15 treatment. (d) b-AP15 inhibits de-ubiquitination of Hdm2. Ubiquitinated Hdm2 
was added to DMSO or b-AP15 (50 µM) treated 19S RP followed by 
immunoblotting. (e) Ubiquitin chain disassembly reactions of K63/K48 linked 
ubiquitin tetramers by 19S RP following treatment with DMSO or b-AP15 (50 µM).  
 
Figure 3: b-AP15 inhibits the 19S RP DUBs UCHL5 and USP14. (a) 19S RP were 
pre-treated with DMSO, NEM (10 mM), b-AP15 (50 µM) or b, TPEN (250 µM) 
followed by addition of Ub-GFP followed by immunoblotting with anti GFP 
antibodies. (c) Active site directed labeling of proteasomal. DUBs. Purified 19S or 
26S proteasomes were pre-treated with DMSO, NEM or b-AP15 followed by labeling 
with HA-UbVS and immunoblotting. (d) Immunoblot of HCT-116 cells treated with 
b-AP15 (1 µM) for 3 h. DUBs from whole cell lysates were labeled with HA-UbVS 
followed by SDS-PAGE and immunoblotting with indicated antibodies. 
 
Figure 4: b-AP15 inhibits tumor growth in vivo. (a) SCID mice bearing FaDu 
human tumor xenografts were treated by daily subcutaneous injection with either 
vehicle (n =10) or 5 mg kg-1 b-AP15 (n=15). Mean tumor volume ± SEM are shown. 
(***P=<0.001). (b) Total levels of tumor derived CK18 and caspase cleaved (CK18-
Asp396) in circulation following b-AP15 treatment (**P=0.01). (c) Disease free 
survival of nude mice challenged with HCT-116 Bcl-2+ cells. Mice were treated with 
vehicle (n=6) or 5 mg kg-1 b-AP15 (n=6) 4–5 times weekly for 3 weeks and 
monitored for tumor onset. (log-rank, P=0.0136, hazard ratio = 7.9). (d) C57BL/6J 
mice bearing syngenic lung carcinoma (LLC) tumors were treated with either vehicle 
(n = 4) or 5 mg kg-1 b-AP15 (n=4) in a 1 day on/2 day off cycle. Mean tumor volume 
± SEM are shown. (**P=<0.01). (e) BALB/c mice bearing orthotopic breast 
carcinomas (4T1) were treated with either vehicle (n =5) or 2.5 mg kg-1 b-AP15 (n=5) 
in a 1 day on/3 day off cycle. Mean tumor volume ± SEM are shown. (**P=<0.01). 
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(f) Box and whisker plots of pulmonary metastatic colonies from vehicle or b-AP15 
treated 4T1 breast carcinomas. Boxes represent the upper and lower quartiles and 
median, whiskers show maximum and minimum values. (g) Representative 
immunohistochemical staining for K48-linked ubiquitin accumulation and cleaved 
caspase-3 in vehicle and b-AP15 treated 4T1 tumors (scale bars, 20 µm). (h) AML 
infiltration in liver and ovary of vehicle or treated mice. Liver of vehicle treated mice 
showed invasion of leukemic blasts along with glycogen depletion and non-specific 
hemorrhage. Ovary section of vehicle treated mouse showing massive invasion of 
leukemic blasts and interstitial bleeding. In contrast ovary from showed few 
infiltrated blasts and normal morphology (scale bars, 250 µm).  
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Online Methods 
Drugs. We obtained b-AP15 (NSC687852) 32 from the Developmental Therapeutics 
Program of the US National Cancer Institute (http://www.dtp.nci.nih.gov) or from 
OncoTargeting AB (Uppsala, Sweden). We obtained bortezomib was obtained from 
the Department of Oncology, Karolinska Hospital. For in vivo administration of b-
AP15 we dissolved the drug in Cremphor EL:PEG 400 (1:1) by heating to give a 
working concentration of 2 mg/ml. Working stock was 1:10 diluted in 0.9% normal 
saline immediately prior to injection. 
 
Connectivity Map analysis. We performed the microarray based gene expression 
analysis and the Connectivity Map (CMAP) essentially as described 6. Briefly, MCF7 
cells were exposed to 1 mM b-AP15 for 6 h or vehicle  (0.1 % DMSO, 6 h). RNA was 
isolated (RNeasy miniprep kit, Qiagen) followed by quality control, labeling and 
hybridization to Genome U133 Plus 2.0 arrays (Affymetrix Inc). Raw data was 
normalized using Mas5 (Affymetrix Inc.) and rank ordered. The following criteria for 
selection of the 30 most induced (up tags) and the 30 most suppressed (down tags) 
transcripts were used. Up tags: present call and expression over 300 arbitrary units in 
the b-AP15 experiment. Down tags: present call after both b-AP15 and vehicle 
treatment, and expression over 300 arbitrary units in the vehicle experiment. Only 
tags (i.e. probes) present on HG U133A arrays were used for CMAP compatibility. 
We have deposited raw and normalized expression data at Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE24150. 
 
Proteasome Inhibition assays. We performed in vitro proteasome activity assays 
using 20S CP (2 nM) in reaction buffer (25 mM Hepes, 0.5 mM EDTA, 0.03 % SDS) 
or 26S proteasomes in reaction buffer (25 mM Hepes, 50 mM NaCl, 10 mM MgCl2, 2 
mM ATP, 1 mM DTT). We used 10 µM Suc-LLVY-AMC, Z-LLE-AMC or Boc-
LRR-AMC for the detection of chymotrypsin-like, caspase-like and trypsin-like 
activity respectively using Wallac Multilabel counter equipped with 380 nm 
excitation and 460 nm emission filters. 
 
DUB inhibition assays. For DUB inhibition assays we incubated 19S RP (5 nM), 
26S (5 nM) UCH-L1 (5 nM), UCH-L3 (0.3 nM), USP2CD  (5 nM) USP7CD (5 nM) 
 16 
USP8CD (5 nM) or BAP1 (5 nM) with DMSO or b-AP15 and monitored cleavage of 
ubiquitin-AMC (1000 nM) using Wallac Multilabel counter or Tecan Infinite M1000 
equipped with 380 nm excitation and 460 nm emission filters. 
 
In vivo tumor experiments. For the squamous carcinoma model we subcutaneously 
injected 1×106 FaDu cells into the right rear flank of female SCID mice. We 
measured tumor growth by the formula L × W2 × 0.44. When tumors had grown to a 
size of approximately 200 mm3 (Day 0) mice we randomized mice to receive either 
vehicle (n=10) or b-AP15 5 mg kg-1 by daily subcutaneous injection s.c. (n=15). For 
the colon carcinoma model, we subcutaneously injected 2.5 × 106 Bcl-2 over-
expressing HCT-116 colon carcinoma into the right flank of female nude mice. We 
treated mice with 5 mg kg-1 b-AP15 by intra peritoneal injection (i.p.). For the lung 
carcinoma model we subcutaneously injected 2×105 Lewis Lung Carcinoma (LLC) 
cells into the right rear flank of female C57/B6 mice. When tumors had grown to a 
size of approximately 50 mm3 (Day 0) we randomized mice to receive either vehicle 
(n=4) or b-AP15 5 mg kg-1 i.p. (n=4) with a treatment cycle consisting of two days 
treatment followed by two days rest (2 days on/2 days off) for two weeks. For the 
breast carcinoma model we subcutaneously injected 1×105 4TD cells into the right 
mammary fat pad of female BALB/c mice. When tumors had grown to a size 
approximately 25 mm3 (d 0), we randomized mice to receive either vehicle (n=5) or 
b-AP15 2.5 mg/kg-1 i.p. (n=5) with a treatment cycle consisting of one day treatment 
followed by three days rest (1 day on/3 day off) for 3 weeks. In the AML studies we 
intra venously injected 5 × 105 C1498 AML cells into the tail vein of female 
C57BL/6J mice. After eight days mice we randomized mice to receive either b-AP15 
5 mg kg-1 (n=10) or vehicle (n=10) i.p. for 7 days (d 8 to d 14). Nineteen days after 
malignant cell injection we sacrificed all mice and evaluated histopathological 
manifestations of liver and ovary (target organs for this model of tumor) between 
groups. We conducted all animal experiments in full accordance with Swedish 
governmental and European statutory regulations on animal welfare. Stockholm 
North ethics committee approved experiments using squamous, lung and breast 
carcinoma models. Stockholm South ethics committee approved experiments using 
the AML model. Experiments using the HCT-116 model were approved by the 
Ethical Committee for Animal Experimentation, Istituto Nazionale dei Tumori di 
Milano.  
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Supplementary Figure 1
Supplementary Figure 1: b-AP15 does not induce DNA damage.
HCT-116 cells were treated with b-AP15 (1 μM) or doxorubicin (100 nM, as a positive control for genotoxic 
stress) for 18 h. Cell lysates were immuno-blotted with antibodies for phosphorylated TP53 and histone 
H2AX as a marker for DNA damage or for total levels of TP53 and β -actin as loading controls.
Inhibition of proteasome deubiquitinating activity as a novel cancer therapy.
Pádraig D’Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, 
Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson
and Stig Linder.
Supplementary Figure 2: b-AP15 induces apoptosis and inhibits cell survival of HCT-116 cells whereas
PBMC (periferal blood mononuclear cells) and immortalzied hTERT-RPE1 are less sensitive.
a, HCT-116 cells were treated with increasing concentrations of b-AP15 for 24 h and the levels of apoptosis
were determined by measuring the levels of caspase cleaved cytokeratin-18 (CK18) by ELISA assay.
b, HCT-116 cells were treated with increasing concentrations of b-AP15 for 48 h. Cell viability was determined
by acid-phosphatase activity assay. Mean values ± s.d. shown.
c, HCT-116 or hTERT-RPE1 cells were treated with increasing concentrations of b-AP15 for 72 hr followed by
analysis of cytotoxicity using the FMCA method described.
d, HCT-116 or hTERT-RPE1 cells were treated with increasing concentrations of bortezomib for 72 hr followed by
analysis of cytotoxicity using the FMCA method. hTERT-RPE1 is an immortalized human retinal pigment
epithelial cell line.
e, f, IC50 was determined from log concentration-effect curves in Graph Pad Prism (GraphPad software Inc., 
CA, USA) using non-linear regression analysis (four parameter model with variable Hill slope). Concentration-
response curves were generated in two-fold dilutions at 8 concentrations of b-AP15 and bortezomib in triplicates
 using the FMCA assay. The results are expressed as log IC 50 + SD from 4-5 independent experiments 
(HCT-116, n=5, PBMC (peripheral blood mononuclear cells), n=4, hTERT-RPE1, n=5).
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Supplementary Figure 3
Supplementary Figure 3: Dose response curves of apoptosis induction in isogenic clones 
of HCT-116 cells.
HCT-116 cells were treated with increasing concentrations of bortezomib or b-AP15 for 24 h and the levels 
of apoptosis were determined by measuring the levels of caspase cleaved cytokeratin-18 (CK18) by 
ELISA assay (Mean fold change ± s.d., n=4).
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Supplementary Figure 4 : b-AP15 does not inhibit the proteolytic activities of the proteasome.
a, 20S CP  (2 nM) were pretreated with DMSO, b-AP15 (50 μM) or bortezomib 
(100 nM) for 5 min in assay buffer ( 25 mM HEPES, 0.5 mM EDTA, 0.03% SDS) followed by the addition 
of 100 μM of the fluorogenic substrates Suc-LLVY-AMC, Z-LLE-AMC or Boc-LRR-AMC for  analysis of 
proteasome chymotrypsin-like, caspase-like and trypsin-like activities respectively. 
b, 26S proteasomes (2 nM) in assay buffer (25 mM HEPES, 50 mM NaCl, 10 mM MgCl 2, 2 mM ATP, 1 mM 
DTT) were treated as in a. Values represent the fold cleavage in relative fluorescent units.   
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Supplementary Figure 5. b-AP15 does not cause disassociation of 19S and 20S particles
or alter ubiquitin binding. 
a, Substrate overlay assay of b-AP15 treated proteasomes. Purified 26S proteasome was treated with 
b-AP15 (10,50 μM) separated by native gel electrophoresis and assayed for proteolytic activity 
using Suc-LLVY-AMC as a fluorogenic substrate for peptidase activity. Analysis of gels showed the 
presence of both doubly (RP2CP) and singly (RP1CP) capped proteasomes in both control and 
b-AP15 treated lanes. The addition of 0.03% SDS did not reveal an increase in the presence of 
uncapped 20S core particles. b, b-AP15 does not alter proteasome-ubiquitin binding activity.
HCT-116 cells were treated with bortezomib (100 nM) or b-AP15 (1 μM) and  proteasomes were 
affinity purified .The levels of associated polyubiquitin determined by immunoblotting. 
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Supplementary Figure 6: b-AP15 does not inhibit total DUB activity. 
a, HCT-116 cells were treated for 3 h with b-AP15 (1 μM). Lysates treated with 10 mM N-ethylmaleimide (NEM) 
were included as a control for total DUB inhibition. DUB activity was determined from cell lysates by measuring 
the cleavage  of the fluorogenic substrate ubiquitin-7-amido-4-methylcoumarin (Ub-AMC). 
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Supplementary Figure 7: Biochemical characterization of b-AP15 binding
a, Dose response of b-AP15. Purified 19S proteasomes (5 nM) were treated with indicated
concentrations of b-AP15 and  DUB activity was determined by detectionof Ub-AMC cleavage. 
The IC50 value (2.1±0.411 μM) was determined from log concentration curves in Graph Pad Prism 
using non linear regression analysis. (Mean values ± SD, n=3) .Note that the IC50 observed in 
cell-free assays is somewhat higher than that observed in cells. A likely explanation to this observation 
is that the hydrophobicity of b-AP15 (XLogP = 3.3) leads to enrichment of the compound in cells 9. 
b, Reversibility of b-AP15 inhibition. The reversibility of inhibition was determined by measuring 
recovery of 19S DUB activity after rapid dilution of the enzyme b-AP15 complex. 
A reaction mix containing 50 time the normal 19S concentration used in reactions (250 nM) and 
10 times the calculated IC50 value for b-AP15 (25 μM) was incubated on ice for 15 min followed by
a 50 fold dilution in reaction buffer to give a final concentration of 19S 5nM and b-AP15 0.5 μM.
The linear reaction curves of Ub-AMC cleavage show that b-AP15 is a reversible inhibitor.
c, Experiment was performed as in b, except DMSO and b-AP15 treated proteasomes were purified by
spin purification. The recovery of DUB activity after drug removal further suggests that b-AP15 is a 
reversible inhibitor. 
d, To determine if b-AP15 reacts non specifically with cyteine residues 19S (5 nM) was treated 
with b-AP15 (10μM) or b-AP15 (10 μM) mixed with reduced glutathione GSH (2 mM). 
The presence of glutathione did not reduce b-AP15 mediated inhibition of 19S DUB activity. 
Cleavage of ubiquitin-AMC was monitored using Tecan Infinite M1000 equipped with 380 nm excitation 
and 460 nm emission filters.
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Supplementary Figure 8: b-AP15 is not a general DUB inhibitor. 
a, HCT-116 cells were treated with b-AP15 (1 μM) and proteasomes affinity purified. DUB activity of proteasomes
is expressed as cleavage of Ub-AMC/suc-LLVY-AMC to normalize for proteasome levels 
(P=0.012, unpaired t test, two tailed).  
b, b-AP15 does not inhibit non proteasomeal DUBs. Recombinant non proteasomal DUBs were treated with 
b-AP15 as described and percentage activity was determined.
c, Cell lysates from 293T or HeLa cells were treated with b-AP15 (50 μM) followed by active labelling
 with HA-UbVS. All samples were run on SD-PAGE gels followed by immunoblotting with α-HA 
antibodies. 
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Supplementary Figure 9: b-AP15 treatment does not significantly alter animal weight.
The difference in weight at the start and endpoint between control and treated animals for the
xenografts presented in Fig. 4 was; FaDu, decrease of 1.3%; LLC, increase 2.1% and 4T1, 
increase of 5.8 %. Boxes represent the upper and lower quartiles and median, whiskers show 
maximum and minimum values.
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Supplementary Figure 10: Sensitivity of cell lines in the NCI60 panel to b-AP15 and bortezomib.
Shown are IC50 values for individual cell lines (left) and median IC50 values for each tumor type (right).
Data are from www.dtp.nci.nih.gov. Arrows indicate the two most sensitive tumor cell types for each drug.
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Supplementary Table 1. Induction of chaperone expression after b-AP15 treatment  
 
   
Expression 
values  
Probe Set 
ID Gene Title 
Gene 
Symbol b-AP15 Vehicle 
Fold 
change 
117_at heat shock 70kDa protein 6 (HSP70B') HSPA6 24149 33 725 
225061_at DnaJ (Hsp40) homolog, A4 DNAJA4 21103 711 30 
203810_at DnaJ (Hsp40) homolog, B4 DNAJB4 1955 123 16 
205543_at heat shock 70kDa protein 4-like HSPA4L 5452 406 13 
200666_s_at DnaJ (Hsp40) homolog, B1 DNAJB1 33900 5251 6 
241716_at heat shock 60kDa protein 1  HSPD1 487 77 6 
203811_s_at DnaJ (Hsp40) homolog, B4 DNAJB4 960 178 5 
202581_at heat shock 70kDa protein 1B HSPA1B 31068 6382 5 
206976_s_at heat shock 105kDa/110kDa protein 1 HSPH1 40974 8427 5 
211016_x_at heat shock 70kDa protein 4 HSPA4 1803 422 4 
202843_at DnaJ (Hsp40) homolog, B9 DNAJB9 1879 449 4 
200880_at DnaJ (Hsp40) homolog, A1 DNAJA1 19970 4872 4 
200800_s_at heat shock 70kDa protein 1A  HSPA1A 57478 14352 4 
Supplementary Table 2. Quantitation of chaperone gene induction. 
 
 
  Fold induction# 
Gene Title 
Gene 
Symbol b-AP15 bortezomib 
heat shock 70kDa protein 6 (Hsp70B') HSPA6 1550 60 
heat shock 70kDa protein 1B (Hspa1b) HSPA1B 21 12 
DnaJ homolog, B1 (Hsp40B1) DNAJB1 22 5 
HCT116 cells were treated with IC90 concentrations of b -AP15 or bortezomib and 
mRNA levels were determined after reverse transcription and real time PCR. Fold 
induction is expressed as fold untreated control. The experiment was repeated with 
similar results.
Supplementary Methods 
 
Reagents. We obtained all reagents from the following sources: 20S proteasome (E-
360), 26S proteasome (E-365), 19S proteasome (E-366), Suc-LLVY-AMC (S-280), 
Z-LLE-AMC (S-230), Boc-LRR-AMC (S-300), Ubiquitin-AMC (U-550), Tetra-
ubiquitin K63 (UC-310), Tetra-ubiquitin K48 (UC-210), deconjugating enzyme set 
(KE10), HA-Ubiquitin Vinyl Sulfone (U-212) (Boston Biochem); anti-β actin (AC-
15), ODC-1 (HPA001536) (Sigma Aldrich); anti-LC-3 (2775), anti-GAPDH (2118), 
anti-p44/42 MAPK (4695), anti-Phospho-p44/42 MAPK (9101)(Cell Signaling); N-
Ethylmaleimide (34115) (EMD Chemicals); anti-Ubiquitin K48 (Apu2), anti-
Ubiquitin (MAB1510) (Millipore); anti-p53 (DO1), anti-UCHL5 (H-110), Hdm2 
(SMP14) (Santa Cruz); anti PARP (C2-10), anti-p27 (G173-524), anti-active Caspase 
3 (C92-605) (BD Biosciences); anti-USP14 (A300-919A) (Bethyl Laboratories); anti-
HA (12CA5)(Roche).  
 
Cell culture. MCF7 cells were maintained in MEM/10% fetal calf serum. HCT-116 
p53+/+, p53–/–, Bcl-2+ , BBC3–/– and BAX–/– cells were maintained in McCoy´s 5A 
modified medium/10% fetal calf serum. The HCT-116 p53+/+ p53–/–, BBC3–/– and 
BAX–/–  cells were generated as described 1. We generated the HCT-116 Bcl-2+  cell 
line by transfecting parental HCT-116 p53+/+cells with pCEP4 Bcl-2 (Addgene 
plasmid 16461) 2 and isolating high expression clones . FaDu and LLC3 cells were 
maintained in DMEM high glucose medium supplemented with 10% fetal calf serum, 
Na pyruvate, Hepes and non-essential amino acids. 4T1.12B carcinoma cells were 
maintained in RPMI medium supplemented with 10% fetal calf serum. The 
proteasome reporter cell line MelJuSo Ub-YFP was generated as described 3. Cells 
were maintained in Dulbecco’s Modified Eagle’s Medium/ 10 % fetal calf serum. The 
retinal epithelial cell line was generated as described 4. All cells were maintained at 
37oC in 5% CO2.  
 
Determination of cell apoptosis and viability. We seeded cells in 96-well microtiter 
plates at 10,000 cells per well and incubated overnight. Cells were treated with 
indicated drug for 24 h. At the end of the incubation period, NP40 was added to the 
tissue culture medium to 0.1 % and 25 µl of the content of each well was assayed 
using the M30-Apoptosense® ELISA as previously described 6.  We determined cell 
viability by measuring acid phosphatase activity or by FMCA 7. For the acid 
phosphatase activity cells were seeded at 5,000 cells per well in 96-well culture plates 
and incubated for 12 h at 37oC. Compounds were added to the cells in growth media 
and incubated for 72 h at 37oC. Cells were washed with 200 µl warm PBS. 100 µl of 
para-nitrophenyl phosphate (pNPP, 2mg/ml) in Na acetate buffer pH 5 (NaAc 0.1 M, 
0.1% Triton-X-100) was added per well. Cells were incubated for 2 h after which 
reaction was stopped by addition of 1N NaOH. Absorbance was measured at 405 nm. 
For the FMCA assay cells were seeded in the drug-prepared 384-well plates using the 
pipetting robot Precision 2000 (Bio-Tek Instruments Inc., Winooski, VT). The plates 
were incubated for 72 h and then transferred to an integrated HTS SAIGAN Core 
System consisting of an ORCA robot (Beckman Coulter) with CO2 incubator 
(Cytomat 2C, Kendro, Sollentuna, Sweden), dispenser module (Multidrop 384, 
Titertek, Huntsville, AL), washer module (ELx 405, Bio-Tek Instruments Inc), 
delidding station, plate holder, barcode reader (Beckman Coulter), liquid handler 
(Biomek 2000, Beckman Coulter) and a multipurpose reader (FLUOstar Optima, 
BMG Labtech GmbH, Offenburg, Germany) for automated FMCA. Survival index 
(SI) is defined as the fluorescence of test wells in percentage of controls with blank 
values subtracted. 
 
Substrate overlay assays. We performed native gel electrophoresis essentially as 
described 5. In brief 4 µg of purified 26S proteasome (Boston Biochem) was mixed 
with 10 or 50 µM b-AP15 and incubated at 37oC for 10 min. We resolved samples on 
4% non-denaturing PAGE and submerged gels in assay buffer (20 mM Tris-HCL, 5 
mM MgCl2, 1 mM ATP, 0.1 mM Suc-LLVY-AMC) and visualized proteasomes 
under UV illumination.  
 
Ubiquitin-cleavage assay. The recombinant Ub-GFP plasmid pet19b Ub-M-GFP was 
generated as described 23. We purified recombinant Ub-GFP from BL21 e.coli cells 
by His affinity purification. For cleavage assays we incubated 19S RP (25 nM) with 
10 mM NEM, 250 µM TPEN or 50 µM b-AP15 for 10 min followed by the addition 
of recombinant Ub-GFP (200 nM). We performed ubiquitin chain disassembly 
reactions as above except K48- or K63-linked ubiquitin tetramers (50 ng) were 
substituted for Ub-GFP. We generated the ubiquitinated HDM2 substrate according to 
the Boston Biochem protocol (K-200). For the cleavage assay we incubated 19S RP 
(25 nM) with 50 µM b-AP15 or DMSO for 10 min followed by the addition of 
ubiquitinated HDM2 (100 nM). 
 
Proteasome isolation: We treated HCT-116 cells with bortezomib (100 nM) or b-
AP15 (1 µM) for 3 hours. We lysed in 50 mM HEPES pH 7.4, 250 mM sucrose, 10 
mM MgCl2, 2 mM ATP, 1 mM DTT and 0.025 % digitonin.  Samples were sonicated 
briefly followed by incubation on ice and proteasomes were isolated according to 
manufacturers protocol.  
 
UbVS labeling. We lysed cell pellets from control or treated cells with buffer (50 
mM HEPES pH 7.4, 250 mM sucrose, 10 mM MgCl2, 2 mM ATP, 1 mM DTT) on ice 
for 15 min and removed debris by centrifugation. We labeled 25 µg of protein with 1 
µM HA-UbVS for 30 min at 37oC. We resolved samples by SDS-PAGE and 
performed immunoblotting.  
 
Cell-cycle analysis. For determination of cell cycle HCT-116 cells were treated with 
b-AP15 or DMSO Cells were harvested by trypsinisation, washed and fixed in 70% 
ice cold EtOH for 12 h. Cells were re-suspended in staining solution containing 
propidium iodide (50 µg/ml) and RNAse A (0.5 µg/ml) in PBS. Samples were run on 
BD FACScalibur. The percentage of cells in each phase of the cell cycle was 
determined using ModFit software. 
 
Determination of pulmonary metastases. Since the 4T1 cells are resistant to 6-
thioguanine, metastases can be determined by culturing homogonized tissue in the 
presence of 6-thioguanine. For determination of metatastic 4T1 cells the protocol was 
as described 8. In brief lungs from treated or untreated animals were homogenized and 
treated with collagenase and elastase. Cells were grown in the presence of 60 µM 6-
thioguanine for 2 weeks and the number of metastatic colonies determined by giemsa 
staining.   
 
Determination of caspase-cleaved CK18 in mouse plasma. For measurement of the 
apoptosis-related CK18-Asp396 fragment, 12.5 ml of plasma was collected 24 h after 
last treatment and analyzed using the M30 M30-Apoptosense® assay. Each sample 
was mixed with 0.4 ml of heterophilic blocking reagent (Scantibodies laboratory Inc). 
Immunostaining. Tumor sections were de-paraffinised with xylene, rehydrated and 
then incubated over-night with K-48 ubiquitin or active-caspase 3 (1/500) diluted in 
1% (wt/vol) bovine serum albumin and visualized by standard avidin–biotin–
peroxidase complex technique (Vector Laboratories). Counterstaining was performed 
with Mayer's haematoxylin.  
Statistical analyses. For comparisons of treatment groups, we performed the 
unpaired t test (Mann-Whitney), repeated measures ANOVA and Kaplan-Meier 
survival (Mantel-Cox test). All statistical analyses were performed using GraphPad 
Prism Software (version 5.0). Statistical significance was achieved when P was less 
than 0.05. 
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